Xvivo Perfusion AB Statistics

Total Valuation

Xvivo Perfusion AB has a market cap or net worth of SEK 15.40 billion. The enterprise value is 14.95 billion.

Market Cap	15.40B
Enterprise Value	14.95B

Important Dates

The next estimated earnings date is Thursday, October 24, 2024.

Earnings Date	Oct 24, 2024
Ex-Dividend Date	n/a

Share Statistics

Xvivo Perfusion AB has 31.50 million shares outstanding. The number of shares has increased by 3.61% in one year.

Shares Outstanding	31.50M
Shares Change (YoY)	+3.61%
Shares Change (QoQ)	+0.37%
Owned by Insiders (%)	0.43%
Owned by Institutions (%)	44.22%
Float	25.00M

Valuation Ratios

The trailing PE ratio is 124.58 and the forward PE ratio is 115.33.

PE Ratio	124.58
Forward PE	115.33
PS Ratio	21.53
PB Ratio	7.61
P/FCF Ratio	2,664.00
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 197.98, with an EV/FCF ratio of 2,585.55.

EV / Earnings	123.82
EV / Sales	21.40
EV / EBITDA	197.98
EV / EBIT	n/a
EV / FCF	2,585.55

Financial Position

The company has a current ratio of 4.13, with a Debt / Equity ratio of 0.01.

Current Ratio	4.13
Quick Ratio	3.27
Debt / Equity	0.01
Debt / EBITDA	0.36
Debt / FCF	4.70
Interest Coverage	35.97

Financial Efficiency

Return on equity (ROE) is 6.84% and return on invested capital (ROIC) is 1.49%.

Return on Equity (ROE)	6.84%
Return on Assets (ROA)	1.32%
Return on Capital (ROIC)	1.49%
Revenue Per Employee	4.60M
Profits Per Employee	794,316
Employee Count	160
Asset Turnover	0.34
Inventory Turnover	1.22

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +84.53% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+84.53%
50-Day Moving Average	508.35
200-Day Moving Average	390.77
Relative Strength Index (RSI)	42.15
Average Volume (20 Days)	21,975

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Xvivo Perfusion AB had revenue of SEK 698.73 million and earned 120.74 million in profits. Earnings per share was 3.93.

Revenue	698.73M
Gross Profit	518.18M
Operating Income	42.81M
Pretax Income	129.17M
Net Income	120.74M
EBITDA	64.86M
EBIT	42.81M
Earnings Per Share (EPS)	3.93

Full Income Statement

Balance Sheet

The company has 480.77 million in cash and 27.19 million in debt, giving a net cash position of 453.58 million or 14.40 per share.

Cash & Cash Equivalents	480.77M
Total Debt	27.19M
Net Cash	453.58M
Net Cash Per Share	14.40
Equity (Book Value)	2.02B
Book Value Per Share	64.28
Working Capital	629.03M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 69.30 million and capital expenditures -63.52 million, giving a free cash flow of 5.78 million.

Operating Cash Flow	69.30M
Capital Expenditures	-63.52M
Free Cash Flow	5.78M
FCF Per Share	0.18

Full Cash Flow Statement

Margins

Gross margin is 74.16%, with operating and profit margins of 6.13% and 17.28%.

Gross Margin	74.16%
Operating Margin	6.13%
Pretax Margin	18.49%
Profit Margin	17.28%
EBITDA Margin	9.28%
EBIT Margin	6.13%
FCF Margin	0.83%

Dividends & Yields

Xvivo Perfusion AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.61%
Shareholder Yield	-3.61%
Earnings Yield	0.80%
FCF Yield	0.04%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Xvivo Perfusion AB has an Altman Z-Score of 23.83.

Altman Z-Score	23.83
Piotroski F-Score	n/a